- Potential to bring in-house cell-based therapies that potentiate checkpoint inhibitors
ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc., (ITI) a privately held clinical-stage biotechnology company focused on advancing its proprietary nucleic acid immunotherapy platform, announced today an exclusive option to license or acquire a series of innovative technologies in the immuno-oncology space from iOncologi, Inc., (iOi).
Preclinical studies led by iOi Co-Founders, Drs. Duane Mitchell and Catherine Flores, have demonstrated that resistance to immune checkpoint inhibitors (ICIs) can be overcome by iOis novel, intravenously delivered stem cell-based therapeutic. Rapid translation of this possible breakthrough discovery into first-in-human clinical trials is underway. ITIs option offers potential opportunities for both companies to further facilitate clinical and commercial development in the field of cell therapy and for collaboration in the development of nucleic acid vaccines that complements ITIs own UNITE technology. The option agreement contemplates additional investment by ITI dependent upon iOi achieving certain clinical trial milestones.
We are pleased to expand our collaboration with Dr. Duane Mitchell, both in his role as Founder & President of iOncologi, and as a leading academic researcher in the immuno-oncology field. Dr. Mitchell has been instrumental in the development and leadership of our ATTAC-II clinical trial for patients with Glioblastoma, said Dr. William Hearl, CEO of Immunomic Therapeutics. His determination to bring innovative treatments to patients is what compounds the complementary technologies in both companies.
We are very excited to have iOncologi and Immunomic Therapeutics bring together complementary expertise in the advancement of new treatments for patients with refractory cancers, said Dr. Mitchell. This agreement expands upon a longstanding and very fruitful collaboration with Dr. Hearl and the team at ITI in bringing forward novel immunotherapy treatments for patients with Glioblastoma. I look forward to the advances that will come from this agreement between the two companies.
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including antigen-derived antibodies as biologics. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease and allergy. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Fred Hutchinson Cancer Research Institute, Johns Hopkins University of Medicine, and Duke University School of Medicine. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit http://www.immunomix.com.
About iOncologi, Inc.
iOncologi, Inc. (iOi) is a privately held biotechnology company focused on the advancement of novel immunotherapies for the treatment of refractory cancers and infectious diseases. iOis core platform technology involves the proprietary use of intravenously delivered stem cells to overcome resistance to immune checkpoint inhibitors (ICIs) in a variety cancers. iOi holds particular expertise in the treatment of malignant brain tumors and is focused on advancing its immunomodulatory stem cell therapy for adult and pediatric patients with malignant gliomas, as well as for patients with brain metastasis. iOis stem cell therapy has also demonstrated a capacity to enhance the effectiveness of adoptive T cell therapy and holds significant potential in the treatment of severe infectious diseases and sepsis. iOi maintains its headquarters at The Hub at Innovation Square in Gainesville, Florida.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123006210/en/
More:
Immunomic Therapeutics Announces Collaboration With iOncologi - BioSpace
- Stem-cell therapy - Wikipedia - December 30th, 2022 [December 30th, 2022]
- Stem Cell Transplantation: What it Is, Process & Procedure - December 30th, 2022 [December 30th, 2022]
- Stem Cell Therapy for Arthritis | Arthritis-health - December 30th, 2022 [December 30th, 2022]
- FDA Warns About Stem Cell Therapies | FDA - U.S. Food and Drug ... - December 30th, 2022 [December 30th, 2022]
- Induced pluripotent stem cell - Wikipedia - December 30th, 2022 [December 30th, 2022]
- Stem cell - Wikipedia - November 28th, 2022 [November 28th, 2022]
- Types of Stem Cell and Bone Marrow Transplants - American Cancer Society - November 28th, 2022 [November 28th, 2022]
- Novel stem cell therapy for repair of knee cartilage - Mayo Clinic - November 28th, 2022 [November 28th, 2022]
- Celebrities Are Officially Being Sued by FTX Retail Investors - November 20th, 2022 [November 20th, 2022]
- FDA Gives First Go Ahead for Lab Grown Meat Product - November 20th, 2022 [November 20th, 2022]
- Sam Bankman-Fried Admits the "Ethics Stuff" Was "Mostly a Front" - November 20th, 2022 [November 20th, 2022]
- "Elon" Plummets in Popularity as a Baby Name for Some Reason - November 20th, 2022 [November 20th, 2022]
- Celebrities' Bored Apes Are Hilariously Worthless Now - November 20th, 2022 [November 20th, 2022]
- Startup Says It's Building a Giant CO2 Battery in the United States - November 20th, 2022 [November 20th, 2022]
- Panicked Elon Musk Reportedly Begging Engineers Not to Leave - November 20th, 2022 [November 20th, 2022]
- Former Facebook Exec Says Zuckerberg Has Surrounded Himself With Sycophants - November 20th, 2022 [November 20th, 2022]
- Experts Baffled by Why NASA’s “Red Crew” Wear Blue Shirts - November 20th, 2022 [November 20th, 2022]
- NASA Drops Stunning New James Webb Image of a Star Being Born - November 20th, 2022 [November 20th, 2022]
- Ticketmaster May Have Finally Met Its Match: Furious Swifties - November 20th, 2022 [November 20th, 2022]
- Elon Musk Locks Twitter Employees Out Office, Then Asks Them to Meet Him on the 10th Floor - November 20th, 2022 [November 20th, 2022]
- NASA Tells Astronauts That Tweeting Isn't As Important as Staying Alive - November 20th, 2022 [November 20th, 2022]
- NASA Orders Press Not to Photograph Launch Site After Moon Mission Takes Off - November 20th, 2022 [November 20th, 2022]
- Amazing Map Lets You Scroll Through the Entire Known Universe - November 20th, 2022 [November 20th, 2022]
- Experts Excoriate NASA Report Claiming James Webb Wasn't Homophobic - November 20th, 2022 [November 20th, 2022]
- So Many People Are Using a Diabetes Drug for Weight Loss That Actual Diabetics Are Having Trouble Getting It - November 20th, 2022 [November 20th, 2022]
- Behind the Lawsuit Against Celebs Who Shilled FTX Before Its Spectacular Meltdown - November 20th, 2022 [November 20th, 2022]
- Twitter Claims Video of Moon Rocket Launch Is Revenge Porn - November 20th, 2022 [November 20th, 2022]
- Manslaughter Case Has a Strange Twist: Tesla That Killed Couple Was on Autopilot - November 4th, 2022 [November 4th, 2022]
- Greta Thunberg Says UN Climate Conference Is a Scam and She's Not Attending - November 4th, 2022 [November 4th, 2022]
- Twitter Working on Plan to Charge Users to Watch Videos - November 4th, 2022 [November 4th, 2022]
- Scientists Use Actual Lunar Soil Sample to Create Rocket Fuel - November 4th, 2022 [November 4th, 2022]
- This Deepfake AI Singing Dolly Parton's "Jolene" Is Worryingly Good - November 4th, 2022 [November 4th, 2022]
- There's Something Strange About How These Stars Are Moving, Scientists Say - November 4th, 2022 [November 4th, 2022]
- NASA Sets Launch Date for Mission to $10 Quintillion Asteroid - November 4th, 2022 [November 4th, 2022]
- Scientists Spot "Stripped, Pulsating Core" of Star Caused By Horrific Accident - November 4th, 2022 [November 4th, 2022]
- Cats May Be Tampering With Crime Scenes, Scientists Say - November 4th, 2022 [November 4th, 2022]
- Elon Musk Meeting With Advertisers, Begging Them Not to Leave Twitter - November 4th, 2022 [November 4th, 2022]
- Scientists Found a Way to Control How High Mice Got on Cocaine - November 4th, 2022 [November 4th, 2022]
- Huge Drone Swarm to Form Giant Advertisement Over NYC Skyline - November 4th, 2022 [November 4th, 2022]
- Hackers Just Took Down One of the World's Most Advanced Telescopes - November 4th, 2022 [November 4th, 2022]
- US Gov to Crack Down on "Bossware" That Spies On Employees' Computers - November 4th, 2022 [November 4th, 2022]
- AOC Says Her Twitter Account Broke After She Made Fun of Elon Musk - November 4th, 2022 [November 4th, 2022]
- China Plans to Send Monkeys to Space Station to Have Sex With Each Other - November 4th, 2022 [November 4th, 2022]
- Chinese Spaceplane Releases Mystery Object Into Orbit - November 4th, 2022 [November 4th, 2022]
- Jeff Bezos' Housekeeper Says She Had to Climb Out the Window to Use the Bathroom - November 4th, 2022 [November 4th, 2022]
- That "Research" About How Smartphones Are Causing Deformed Human Bodies Is SEO Spam, You Idiots - November 4th, 2022 [November 4th, 2022]
- Global Stem Cell Banking Market Research Report 2022: Market to Reach $11.5 Billion by 2026 - Adult Stem Cell Research Gains Traction, Accelerating... - October 27th, 2022 [October 27th, 2022]
- Growing Prevalence & Recurrence Of Rheumatoid Arthritis Is Expected To Growth Of The Rheumatoid Arthritis Stem Cell Therapy Market Designer Women... - July 8th, 2022 [July 8th, 2022]
- Diabetic foot treatment: Here's all you need to know about stem cell therapy - Hindustan Times - July 8th, 2022 [July 8th, 2022]
- Catherine S. Diefenbach, MD, Talks Future of CAR T-cell Therapy Following Liso-Cel Approval in Second-Line LBCL - Cancer Network - July 8th, 2022 [July 8th, 2022]
- Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study | Blood Cancer Journal... - July 8th, 2022 [July 8th, 2022]
- Orthobiologics Market is Predicted to Expand at a CAGR of 4.7% during the Forecast Period, notes TMR Study - GlobeNewswire - July 8th, 2022 [July 8th, 2022]
- Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in... - July 8th, 2022 [July 8th, 2022]
- Global Lupus Market is Expected to Reach USD 4.3 Billion With CAGR of 12.41% By Forecast 2027 Says Maximize Market Research (MMR) - Digital Journal - July 8th, 2022 [July 8th, 2022]
- Jasper Therapeutics to Participate in the William Blair 42nd Annual Growth Stock Conference - GuruFocus.com - July 8th, 2022 [July 8th, 2022]
- TC BioPharm Announces Formation of Scientific Advisory Board with Renowned Cell Therapy Experts - GuruFocus.com - July 8th, 2022 [July 8th, 2022]
- Global Adrenoleukodystrophy Treatment Market Trends, Growth, Opportunities and Forecast to 2029 Designer Women - Designer Women - July 8th, 2022 [July 8th, 2022]
- Mayo Clinic Q and A: Stem cell therapy for arthritis ... - November 29th, 2021 [November 29th, 2021]
- FDA Warns About Stem Cell Therapies | FDA - November 29th, 2021 [November 29th, 2021]
- A Cure for Type 1 Diabetes? For One Man, It Seems to Have Worked. - The New York Times - November 29th, 2021 [November 29th, 2021]
- Cell Therapy Markets, 2030 - ResearchAndMarkets.com - Business Wire - November 29th, 2021 [November 29th, 2021]
- Neuroplast secures 10 million in funding to boost clinical development of stem cell therapy for traumatic spinal cord injuries - Spinal News... - November 29th, 2021 [November 29th, 2021]
- Innovating Reversible Cell Therapies With RNA - Technology Networks - November 29th, 2021 [November 29th, 2021]
- US Stem Cell Therapy Market size and analysis by leading manufacturers, application and types 2021-2027 Energy Siren - Energy Siren - November 29th, 2021 [November 29th, 2021]
- InGeneron Publishes Significant Support for the Existence of Naturally Pluripotent Stem Cells in All Organs in the Adult Body - Galveston County Daily... - November 29th, 2021 [November 29th, 2021]
- Susanna Park inducted as holder of Roth Endowed Chair for Discovery, Education and Patient Care - UC Davis Health - November 29th, 2021 [November 29th, 2021]
- Covid vaccine: Stem cell transplant patients who must be completely re-vaccinated struggling to book jabs - iNews - November 29th, 2021 [November 29th, 2021]
- An Against-the-Odds Cancer Story Can Be Yours - Curetoday.com - November 29th, 2021 [November 29th, 2021]
- Calls for stem cell donation to change in Australia to reduce reliance on overseas donors - ABC News - November 29th, 2021 [November 29th, 2021]
- The Expanding Role of Interferons in Myeloproliferative Neoplasms - Targeted Oncology - November 29th, 2021 [November 29th, 2021]
- Dr. Van Rhee on Future Research Directions for CAR T-Cell Therapy in Multiple Myeloma - OncLive - September 5th, 2021 [September 5th, 2021]
- Cell Therapy Manufacturing Market | Exclusive Report on the Latest Market Trends and Development - PharmiWeb.com - September 5th, 2021 [September 5th, 2021]
- MD Anderson Now to Offer Solution for Cellular Therapy Toxicities - Targeted Oncology - September 5th, 2021 [September 5th, 2021]
- NCCN Issues Updated Guidelines Regarding Third COVID-19 Vaccine Booster for Those With Cancer - Cancer Network - September 5th, 2021 [September 5th, 2021]
- BioRestorative Therapies Receives Patent in Japan Related to its Off-the-Shelf ThermoStem Program - GuruFocus.com - September 5th, 2021 [September 5th, 2021]
- Jury awards North Texas doctor $7.8 million in lawsuit over his partner locking him out - The Dallas Morning News - September 5th, 2021 [September 5th, 2021]
- Iomab-B Shows Early Promise Versus Standard Therapy in Elderly R/R AML - Targeted Oncology - September 5th, 2021 [September 5th, 2021]
- Pirtobrutinib Exhibits Promising Efficacy in Heavily Pretreated MCL and Other Non-Hodgkin Lymphomas - OncLive - September 5th, 2021 [September 5th, 2021]
- MD Anderson and Bellicum Announce Additional License Agreement for Use of CaspaCIDe Safety Switch - Newswise - September 5th, 2021 [September 5th, 2021]
- Hematopoietic Stem Cell Transplantation (HSCT) Market by Sales, Revenue, Price and Gross Margin (2021-2027) UNLV The Rebel Yell - UNLV The Rebel Yell - September 5th, 2021 [September 5th, 2021]